These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
25. Association of PSMA PET-derived Parameters and Outcomes of Patients Treated for Oligorecurrent Prostate Cancer. Murad V; Glicksman RM; Berlin A; Santiago A; Ramotar M; Metser U Radiology; 2023 Dec; 309(3):e231407. PubMed ID: 38051188 [TBL] [Abstract][Full Text] [Related]
26. Stereotactic Radiotherapy for Lesions Detected via Pan J; Wei Y; Zhang T; Liu C; Hu X; Zhao J; Gan H; Liu W; Zhu B; Wu J; Wang B; Song S; Ye D; Zhu Y Eur Urol Oncol; 2022 Aug; 5(4):420-427. PubMed ID: 35304107 [TBL] [Abstract][Full Text] [Related]
27. Prostate-specific membrane antigen-positron emission tomography/computed tomography (PSMA-PET/CT)-guided stereotactic ablative body radiotherapy for oligometastatic prostate cancer: a single-institution experience and review of the published literature. Ong WL; Koh TL; Lim Joon D; Chao M; Farrugia B; Lau E; Khoo V; Lawrentschuk N; Bolton D; Foroudi F BJU Int; 2019 Nov; 124 Suppl 1():19-30. PubMed ID: 31507035 [TBL] [Abstract][Full Text] [Related]
28. Outcome after PSMA-PET/CT-based salvage radiotherapy for nodal recurrence after radical prostatectomy. Rogowski P; Trapp C; von Bestenbostel R; Eze C; Ganswindt U; Li M; Unterrainer M; Zacherl MJ; Ilhan H; Beyer L; Kretschmer A; Bartenstein P; Stief C; Belka C; Schmidt-Hegemann NS Eur J Nucl Med Mol Imaging; 2022 Mar; 49(4):1417-1428. PubMed ID: 34628521 [TBL] [Abstract][Full Text] [Related]
29. Long-term Outcomes of Salvage Lymph Node Dissection for Nodal Recurrence of Prostate Cancer After Radical Prostatectomy: Not as Good as Previously Thought. Bravi CA; Fossati N; Gandaglia G; Suardi N; Mazzone E; Robesti D; Osmonov D; Juenemann KP; Boeri L; Jeffrey Karnes R; Kretschmer A; Buchner A; Stief C; Hiester A; Nini A; Albers P; Devos G; Joniau S; Van Poppel H; Shariat SF; Heidenreich A; Pfister D; Tilki D; Graefen M; Gill IS; Mottrie A; Karakiewicz PI; Montorsi F; Briganti A Eur Urol; 2020 Nov; 78(5):661-669. PubMed ID: 32624288 [TBL] [Abstract][Full Text] [Related]
30. Oncological Outcome of Combining Cytoreductive Prostatectomy and Metastasis-Directed Radiotherapy in Patients with Prostate Cancer and Bone Oligometastases: A Retrospective Cohort Study. Xue P; Wu Z; Wang K; Gao G; Zhuang M; Yan M Cancer Manag Res; 2020; 12():8867-8873. PubMed ID: 33061582 [TBL] [Abstract][Full Text] [Related]
31. More advantages in detecting bone and soft tissue metastases from prostate cancer using Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003 [TBL] [Abstract][Full Text] [Related]
32. Risk Factors for Biochemical Recurrence After PSMA-PET-Guided Definitive Radiotherapy in Patients With Spohn SKB; Birkenmaier V; Ruf J; Mix M; Sigle A; Haehl E; Adebahr S; Sprave T; Gkika E; Rühle A; Nicolay NH; Kirste S; Grosu AL; Zamboglou C Front Oncol; 2022; 12():898774. PubMed ID: 35747822 [TBL] [Abstract][Full Text] [Related]
33. Standard of Care Versus Metastases-directed Therapy for PET-detected Nodal Oligorecurrent Prostate Cancer Following Multimodality Treatment: A Multi-institutional Case-control Study. Steuber T; Jilg C; Tennstedt P; De Bruycker A; Tilki D; Decaestecker K; Zilli T; Jereczek-Fossa BA; Wetterauer U; Grosu AL; Schultze-Seemann W; Heinzer H; Graefen M; Morlacco A; Karnes RJ; Ost P Eur Urol Focus; 2019 Nov; 5(6):1007-1013. PubMed ID: 29530632 [TBL] [Abstract][Full Text] [Related]
34. Event-free survival after Ceci F; Rovera G; Iorio GC; Guarneri A; Chiofalo V; Passera R; Oderda M; Dall'Armellina S; Liberini V; Grimaldi S; Bellò M; Gontero P; Ricardi U; Deandreis D Eur J Nucl Med Mol Imaging; 2022 Jul; 49(9):3257-3268. PubMed ID: 35217883 [TBL] [Abstract][Full Text] [Related]
35. Positron Emission Tomography and Whole-body Magnetic Resonance Imaging for Metastasis-directed Therapy in Hormone-sensitive Oligometastatic Prostate Cancer After Primary Radical Treatment: A Systematic Review. Farolfi A; Hadaschik B; Hamdy FC; Herrmann K; Hofman MS; Murphy DG; Ost P; Padhani AR; Fanti S Eur Urol Oncol; 2021 Oct; 4(5):714-730. PubMed ID: 33750684 [TBL] [Abstract][Full Text] [Related]
36. Progression-free survival in patients with Werensteijn-Honingh AM; Wevers AFJ; Peters M; Kroon PS; Intven M; Eppinga WSC; Jürgenliemk-Schulz IM Acta Oncol; 2021 Oct; 60(10):1342-1351. PubMed ID: 34323648 [TBL] [Abstract][Full Text] [Related]
38. Clinical outcome of PSMA-guided radiotherapy for patients with oligorecurrent prostate cancer. Stefan A Koerber ; Katharina Sprute ; Clemens Kratochwil ; Erik Winter ; Matthias F Haefner ; Sonja Katayama ; Ingmar Schlampp ; Klaus Herfarth ; Klaus Kopka ; Ali Afshar-Oromieh ; Stefanie Zschaebitz ; Tim Holland-Letz ; Peter L Choyke ; Dirk Jaeger ; Markus Hohenfellner ; Uwe Haberkorn ; Juergen Debus ; Frederik L Giesel Eur J Nucl Med Mol Imaging; 2021 Jan; 48(1):143-151. PubMed ID: 32405735 [TBL] [Abstract][Full Text] [Related]